CR11744A - Formulacion liquida para deferiprona con gusto agradable al paladar - Google Patents

Formulacion liquida para deferiprona con gusto agradable al paladar

Info

Publication number
CR11744A
CR11744A CR11744A CR11744A CR11744A CR 11744 A CR11744 A CR 11744A CR 11744 A CR11744 A CR 11744A CR 11744 A CR11744 A CR 11744A CR 11744 A CR11744 A CR 11744A
Authority
CR
Costa Rica
Prior art keywords
deferiprone
palate
liquid formulation
nice taste
taste
Prior art date
Application number
CR11744A
Other languages
English (en)
Inventor
Michael Spino
Anita Hui
Cihua Yang
Mohammed N Kabir
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of CR11744A publication Critical patent/CR11744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación farmacéutica oral líquida que comprende deferiprona y una composición de enmascaramiento del gusto, dicha composición de enmascaramiento de gusto comprende una cantidad efectiva de edulcorante.
CR11744A 2008-04-25 2010-10-20 Formulacion liquida para deferiprona con gusto agradable al paladar CR11744A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2008/000784 WO2009129592A1 (en) 2008-04-25 2008-04-25 Liquid formulation for deferiprone with palatable taste

Publications (1)

Publication Number Publication Date
CR11744A true CR11744A (es) 2011-01-10

Family

ID=41216357

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11744A CR11744A (es) 2008-04-25 2010-10-20 Formulacion liquida para deferiprona con gusto agradable al paladar

Country Status (24)

Country Link
US (1) US8703156B2 (es)
EP (1) EP2268282B1 (es)
KR (1) KR101490721B1 (es)
CN (1) CN102014904B (es)
AP (1) AP2010005454A0 (es)
AU (1) AU2008355464C1 (es)
BR (1) BRPI0822206B8 (es)
CA (1) CA2722393A1 (es)
CR (1) CR11744A (es)
CY (1) CY1116146T1 (es)
DK (1) DK2268282T3 (es)
EA (1) EA022751B1 (es)
ES (1) ES2539414T3 (es)
HR (1) HRP20150083T1 (es)
IL (1) IL208876A (es)
MX (1) MX2010011701A (es)
NZ (1) NZ588602A (es)
PL (1) PL2268282T3 (es)
PT (1) PT2268282E (es)
RS (1) RS53689B1 (es)
SI (1) SI2268282T1 (es)
UA (1) UA102254C2 (es)
WO (1) WO2009129592A1 (es)
ZA (1) ZA201008374B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
CN102712591B (zh) 2009-07-03 2014-06-25 阿普泰克斯科技公司 3-羟基吡啶-4-酮的氟化衍生物
EP2916870A1 (en) 2012-11-12 2015-09-16 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferipone
US20190240144A1 (en) * 2016-05-18 2019-08-08 Khashayar Karimian Effervescent deferiprone tablet
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
JP7246384B2 (ja) 2017-10-25 2023-03-27 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 遅延放出デフェリプロン錠剤及びその使用法
IL278422B (en) * 2019-03-14 2022-09-01 Neuroenergy Ventures Inc A flavor masking formulation for ketone body compounds
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
NL2024161B1 (en) * 2019-11-05 2021-07-20 Mperium B V Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
AU2023313127A1 (en) 2022-07-29 2025-02-13 Drotastar Llc A stable pharmaceutical oral liquid formulation of an antispasmodic agent
CN116459211A (zh) * 2023-03-29 2023-07-21 北京尚修堂医药科技有限公司 一种盐酸奥洛他定口服溶液及制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) * 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
USRE25831E (en) * 1962-12-20 1965-08-03 Method for dyeing acrylonitrile polymer fibers
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308055D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
USRE34313E (en) * 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
GB8329043D0 (en) 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
DE3826846A1 (de) 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) * 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) * 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
FI941777L (fi) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
CN1142821A (zh) 1994-01-31 1997-02-12 辉瑞大药厂 合成γ-吡喃酮的方法
CA2186867C (en) * 1994-04-08 2000-12-12 Donald L. Bissett Methods of using iron chelating compounds to reduce free radical damage in mammals
WO1996003976A1 (en) * 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
KR100801236B1 (ko) 1998-08-28 2008-02-11 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) * 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) * 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2004535370A (ja) * 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
AU2003222513A1 (en) 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
MXPA04008720A (es) * 2002-03-12 2004-12-06 Squibb Bristol Myers Co Suspension oral de sabor agradable y metodo.
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
DE10336497B4 (de) 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
BRPI0509592A (pt) * 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
KR20080104329A (ko) * 2006-02-22 2008-12-02 아놀드 뮤니히 데페리프론의 이용 및 철의 세포 내 미스핸들링으로부터 비롯된 프리드리히 운동실조증의 치료 및/또는 예방 방법
WO2008116301A1 (en) * 2007-03-28 2008-10-02 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds

Also Published As

Publication number Publication date
EA022751B1 (ru) 2016-02-29
MX2010011701A (es) 2010-12-06
UA102254C2 (ru) 2013-06-25
KR101490721B1 (ko) 2015-02-06
RS53689B1 (sr) 2015-04-30
EA201071235A1 (ru) 2011-06-30
SI2268282T1 (sl) 2015-01-30
IL208876A (en) 2015-02-26
HRP20150083T1 (hr) 2015-03-13
DK2268282T3 (en) 2014-11-24
CA2722393A1 (en) 2009-10-29
CN102014904B (zh) 2013-02-06
EP2268282B1 (en) 2014-10-29
ES2539414T3 (es) 2015-06-30
US20110039897A1 (en) 2011-02-17
AP2010005454A0 (en) 2010-12-31
US8703156B2 (en) 2014-04-22
CY1116146T1 (el) 2017-02-08
WO2009129592A1 (en) 2009-10-29
AU2008355464C1 (en) 2014-11-20
HK1152871A1 (en) 2012-03-16
BRPI0822206A2 (pt) 2015-06-23
BRPI0822206B1 (pt) 2019-03-19
EP2268282A4 (en) 2011-06-22
AU2008355464B2 (en) 2014-04-10
CN102014904A (zh) 2011-04-13
BRPI0822206B8 (pt) 2021-05-25
NZ588602A (en) 2012-08-31
EP2268282A1 (en) 2011-01-05
ZA201008374B (en) 2012-01-25
PL2268282T3 (pl) 2015-04-30
KR20100135316A (ko) 2010-12-24
AU2008355464A1 (en) 2009-10-29
PT2268282E (pt) 2015-02-05
IL208876A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
ECSP10010295A (es) Formulacion de anticuerpo
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
AR069875A1 (es) Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
CU20100230A7 (es) Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
ECSP099776A (es) Moduladores de la gamma secretasa
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
AR082215A1 (es) Composicion farmaceutica agradable al paladar
ECSP12011618A (es) Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
WO2010099510A3 (en) Amino acid-based compounds, their methods of use, and methods of screening
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
BRPI0920878A2 (pt) inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
CO6720980A2 (es) Composiciones bucales
EA200901591A1 (ru) Фармацевтические композиции производных s-алкилизотиоурония с маскированным вкусом
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
CO6751242A2 (es) Combinación y composición para el tratamiento de obesidad
UY32197A (es) Sinergismo antibiotico
ECSP11011212A (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)